This joint comment letter from AABB, America’s Blood Centers, and the American Red Cross in response to the FDA’s draft guidance on reducing the risk of Hepatitis C transmission through cellular and tissue-based products support the FDA’s new recommendations and call for clear timeframes for risk assessment of sexual partners, alignment of donor criteria with blood donation guidelines, and an extended implementation period of one year to adapt to the changes.
Posted in Letters and Comments